Explore federal awards
Date filters select awards with transaction activity in the period. Amounts below are lifetime award obligations. IDV values remain separate.
Export these results to CSV · 12 matching records
TRIPLE NEGATIVE BREAST CANCER VACCINESDepartment of Health and Human Services$1.1M obligationsEnds Sep 13, 2028
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: COLORECTAL CANCER (CRC) PREVENTION BY…Department of Health and Human Services$1.1M obligationsEnds Sep 10, 2027
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201 BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY…Department of Health and Human Services$982.3K obligationsEnds Aug 7, 2027
TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCER IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE…Department of Health and Human Services$760.6K obligationsEnds Jun 16, 2026
PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMADepartment of Health and Human Services$1.0M obligationsEnds Sep 14, 2026
BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: FURTHER DEVELOPMENT OF…Department of Health and Human Services$1.2M obligationsEnds Mar 24, 2028
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCERDepartment of Health and Human Services$1.1M obligationsEnds Nov 15, 2025
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.Department of Health and Human Services$910.0K obligationsEnds Nov 1, 2026
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDEDepartment of Health and Human Services$1.4M obligationsEnds Feb 4, 2027
CHEMOPREVENTION WITH MITOCHONDRIA-TARGETED HONOKIOL IN MOUSE MODELS OF LUNG CANCER: ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMADepartment of Health and Human Services$1.2M obligationsEnds Mar 14, 2026
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY…Department of Health and Human Services$780.9K obligationsEnds Jun 20, 2025
TASK ORDER TITLE: PREVENTING COLORECTAL CANCER USING TRAIL-INDUCING ONC201 ALONE OR IN COMBINATION WITH NSAIDDepartment of Health and Human Services$878.8K obligationsEnds Mar 14, 2025